NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT02595762

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer

Countries: Cyprus, Greece

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of HER2-positive unresectable LABC or MBC within 6 months prior to enrollment

Exclusion Criteria:

* None specified

Locations (12)

Nicosia, Cyprus
Athens, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Athens, Greece
Haidari, Greece
Piraeus, Greece
Thessaloniki, Greece
Thessaloniki, Greece